AAAtıl Avcı

Atıl Avcı

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Atıl Avcı has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Social Media‐Driven Cosmetic Consumption With Skin Barrier Damage, Delayed Medical Consultation, and Disease Severity in Acne Vulgaris: A Physician‐Assessed Cross‐Sectional Study

    by Orhan Şen, Atıl Avcı

    Objective: Social media content influences cosmetic consumption among acne patients; however, its clinical consequences remain incompletely understood. This study aimed to evaluate the association of social media‐driven cosmetic consumption, information sources, and cosmetic awareness levels with clinical outcomes (barrier damage, acne severity, delayed medical consultation) in acne vulgaris patients. Methods: A cross‐sectional, descriptive study was conducted in 408 acne patients presenting to a dermatology outpatient clinic. Social media usage habits, dermocosmetic term awareness, and product consumption behaviors were assessed using a structured data collection form, while acne severity, barrier damage, and cosmetic polypharmacy history were evaluated by an attending dermatologist. Data were analyzed using chi‐square test, Mann–Whitney U test, Spearman correlation, and multivariate logistic regression. Results: The mean age of participants was 20.9 ± 5.1 years, and 77.5% were female. Barrier damage was significantly higher in patients who purchased products through social media (64.3% vs. 10.2%; p < 0.001). In multivariate analysis, social media‐driven product purchase (OR = 3.25; p = 0.002) and delayed medical consultation (OR = 6.65; p < 0.001) were identified as independent risk factors for barrier damage. TikTok users exhibited greater delays in seeking medical care (66.7% vs. 49.0%; p = 0.028) and higher rates of severe acne compared with Instagram users. Paradoxically, a higher number of known dermocosmetic terms was associated with increased barrier damage risk and delayed consultation, a pattern that may reflect superficial rather than clinically applicable knowledge. Conversely, following dermatologist accounts emerged as an independent protective factor against barrier damage (OR = 0.28; p = 0.001). Conclusion: Social media‐driven cosmetic consumption is strongly associated with barrier damage and worsening clinical disease severity in acne patients. Increasing evidence‐based content production by dermatologists on social media platforms may positively contribute to the patient care process.

  • Open Access

    Use of Traditional Treatment Methods, Adverse Clinical Findings, and Treatment Adherence in Patients with Cutaneous Verruca: A Cross-Sectional Study

    by Orhan Şen, Atıl Avcı

    Purpose: Cryotherapy is one of the most frequently applied and easily accessible standard methods for treating cutaneous verruca in outpatient settings. This study aimed to determine the frequency of traditional and self-applied treatment methods in patients with cutaneous verruca treated with cryotherapy; to examine their relationship with illness perception, sociodemographic characteristics, and folk beliefs; and to evaluate their effects on adverse clinical findings, quality of life, and cryotherapy adherence.Methods: This cross-sectional, descriptive study included 100 patients with cutaneous verruca. Sociodemographic and clinical data were collected by the investigating physician through face-to-face interviews; the Dermatology Life Quality Index (DLQI) was self-completed by the patients. Patients were classified based on self-reported traditional method use post-data collection without prior grouping. Non-parametric tests, chi-square/Fisher tests, and multivariable logistic regression were used for data analysis.Results: Overall, 47% of patients used at least one traditional method. Adverse clinical findings occurred in 68% of traditional method users compared to 25% of non-users (p

  • Open Access

    Evaluation of the Association of Novel and Conventional Inflammation Indices with Acne Vulgaris Severity: A Retrospective Case-Control Study

    by Orhan Şen, Atıl Avcı

    Purpose: We set out to quantify conventional (NLR, PLR) alongside newer multicellular inflammatory indices (SII, SIRI, AISI) in acne vulgaris (AV), and to determine how closely each tracks clinical severity. Materials and Methods: Records of 230 individuals carrying a clinical AV diagnosis were reviewed retrospectively against 265 controls frequency-matched for age and sex, yielding a study population of 495. Within the AV arm, cases were assigned to mild, moderate, or severe categories. The five indices were derived from routinely obtained blood count parameters and compared across arms.Results: Four of the five indices — NLR, SIRI, AISI and SII — separated the AV arm from controls (p

  • Open Access

    Biologic therapy in geriatric psoriasis: 6-month real-world data on PASI, inflammatory indices, and hepatitis B/tuberculosis safety

    by Esranur Ünal, Beste Pakırdaşı, Selma Emre, Muhammed Burak Yücel, Burak Celik, Esma Nur Özbek, Nurşah Gedikli, Atıl Avcı, Ragıp Ertaş, Orhan Yıldız

    Real-world evidence regarding biologic therapy in geriatric psoriasis is limited, particularly concerning systemic inflammatory burden and infection-related safety. This study evaluates the clinical efficacy of biologic therapy and its impact on systemic inflammatory indices while emphasizing safety related to hepatitis B virus (HBV) serology and tuberculosis screening. We conducted a retrospective analysis of eighty biologic-naïve patients aged 65 years and older with plaque psoriasis undergoing biologic therapy. Patients were categorized by biologic class: tumor necrosis factor-α (TNF-α) inhibitors, interleukin-17 inhibitors, an interleukin-12/23 inhibitor, and interleukin-23 inhibitors. The primary outcomes included changes in Psoriasis Area and Severity Index (PASI) scores and blood count-derived inflammatory indices over time (baseline and 6 months). Secondary outcomes encompassed changes in HBV serologic status and QuantiFERON-TB (QFT) results. Data analysis utilized longitudinal mixed-effects models for repeated measures. Blood count-derived inflammatory indices, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), were assessed at baseline and 6 months, alongside HBV serology and QFT results. PASI scores demonstrated significant improvement over time (p < 0.001), with no notable differences among biologic classes after adjusting for baseline covariates. Significant time effects were observed for all inflammatory indices (all p < 0.001), with significant group × time interactions noted for SII and NLR (both p < 0.05). Variability in HBV serologic markers and QFT results was observed during follow-up; however, no cases of active tuberculosis or clinically overt hepatitis were identified. In conclusion, biologic therapy led to substantial clinical improvement in geriatric psoriasis, accompanied by reductions in systemic inflammatory indices over a 6-month period, without evidence of clinically overt hepatitis or active tuberculosis during follow-up.

  • ATOPİK DERMATİT TEDAVİSİNDE BİYOLOJİK İLAÇLAR: LİTERATÜR TARAMASI

    by Furkan Çalıcıoğlu, Neşecan Çalıcıoğlu, Atıl Avcı, Yılmaz Ulaş, Ragıp Ertaş

    Atopik dermatit; kronik, kaşıntılı, inflamatuar bir deri hastalığıdır. Pediatrik dönemde ve erişkinlik döneminde görülebilen atopik dermatit; kaşıntı, kaşıntıya bağlı uyku bozuklukları, sosyal geri çekilme ve tedavi maliyetleri açısından hastanın yaşam kalitesini doğrudan etkilemektedir. Topikal tedaviler, fototerapi yöntemleri, sistemik immünsupresif ilaçlar ve biyolojik ajanlar atopik dermatit tedavisinde kullanılmaktadır. Biyolojik ajanlar; hızlı etki başlangıçları ve kaşıntının sürdürülebilir kontrolünde oldukça önemli bir rol üstlenmektedir. Semptomların kontrolünde etkili ilaçlar olmaları ve konvansiyonel immünsupresif ilaçlara göre daha az yan etkiye sahip olmaları sebebiyle biyolojik ajanlar atopik dermatit tedavisinde gelecekte daha sık kullanılabilir. Atopik dermatit tedavisi ile ilgili araştırmalar sürdükçe yeni biyolojik ilaçlar üretilmeye ve kullanılmaya devam edecektir. Atopik dermatit tedavisinde kullanılan biyolojik ajanların faz çalışmalarının sonuçlarını ve gerçek yaşam verilerini sentezleyerek paylaşmak istiyoruz. Farklı mekanizmalar üzerinden ilaçların etkilerini, vaka sonuçlarını, karşılaşılan yan etkileri, tedavi sürdürülebilirliğini ve uzun dönem risklerini bir bütün olarak ortaya koymayı ve tartışmayı amaçlıyoruz.

  • Atopik Dermatit Güncel Patofizyolojisi

    by Furkan Çalıcıoğlu, Atıl Avcı, Ragıp Ertaş, Yılmaz Ulaş

    Özet : Atopik dermatit (AD); en sık çocuklarda görülen kronik, kaşıntılı, inflamatuar bir cilt hastalığıdır. Genetik ve çevresel faktörlerin etkisiyle ciltte meydana gelen hastalık, genellikle bebeklik döneminden itibaren bulgu vermeye başlar. Ekzema, enfeksiyonlar, kaşıntı, kaşıntıya bağlı ortaya çıkan uyku bozuklukları hastaların hayat kalitesini doğrudan ve olumsuz etkilemektedir. Amaç: Dermatologlar AD tanısında ve tedavisinde genellikle primer hekimlerdir; ancak eşlik eden/edebilecek komorbiditeler nedeniyle tedaviler multidisipliner bir yaklaşımla ele alınmalıdır. AD patofizyolojisini güncel çalışmalarla ve son verilerle ortaya koymak, sıklığı artan vakaların tedavisinin daha bilinçli ve rasyonel sürdürülmesinde klinisyenlere yardımcı olmak istemekteyiz. Gereç ve yöntem: AD patogenezi ile ilgili özellikle son 5 yılda yapılan çalışmalar; Pubmed, Uptodate ve Clinicalkey üzerinden taranmıştır. Veriler, ulaşılan sonuçlar birleştirilerek tablolarla ve figürlerle özetlenmiştir. Bulgular: AD’de akut dönemde Th2, kronik dönemde Th1 yanıtı baskındır. Epidermal bariyer disfonksiyonu ve kuruluk; özellikle IL-2,4,5,13,17,22,31,33 etkisiyle ve JAK-STAT hücre içi sinyal iletim yolaklarıyla ortaya çıkar. Sonuç: AD patogenezinde; inflamasyonda IL-4, IL-5, IL-13 ile birlikte IL-22 ve IL-31 de önemli rol oynamaktadır.Kaşıntının oluşmasında ve tetikleyicilere hassasiyetin artmasında görevli bu mediatörler, yeni tedavi hedeflerini oluşturmaktadır.Th1,Th17 ve Th22; diğer hücrelerle birlikte inflamasyon yanıtını derinleştiren kilit hücrelerdir.

  • Open Access

    Evaluation of atrial conduction properties and atrial arrhythmia propensity in vitiligo patients

    by Zeki Çetinkaya, Şaban Keleşoğlu, Gökhan Ergün, Yücel Yılmaz, Mustafa Gök, Muhammed Reşat Akkuş, Bekir Çalapkorur, Atil Avcı, Ragıp Ertaş

    Aims: Vitiligo is a skin condition characterized by melanocyte loss. It is thought to have a robust association with various systemic and metabolic disorders, such as insulin resistance, atherosclerotic cardiovascular disease, and metabolic syndrome. Atrial fibrillation (AF) is a prevalent disorder in clinical practice and appears to be predictable by atrial electromechanical delay (EMD). This study aimed to detect atrial conduction time through tissue Doppler echocardiography, a non-invasive method used for patients with vitiligo. Methods: We conducted this study with 32 patients diagnosed with generalized vitiligo and 38 age- and sex-matched controls. We evaluated all participants' blood samples, including neutrophil/lymphocyte ratio (NLR), high-sensitivity C-reactive protein (hs-CRP), and other laboratory parameters. Then, we calculated atrial EMD, intra-atrial EMD, and left atrial EMD. Results: We found neutrophil count, NLR levels, and hs-CRP levels to be significantly higher in the vitiligo group (6 ± 1.4 vs. 4.5 ± 2.3, p = 0.001; 3.5 ± 1.4 vs. 2.5 ± 1.9, p = 0.024; 6.2 ± 1.9 mg/dl vs. 4.1 ± 1.3 mg/dl, p < 0.001, respectively). In addition, inter-atrial and intra-atrial EMD were significantly higher in the vitiligo group compared to the control group (36.3 ± 8.5 vs. 24.2 ± 10.8, p < 0.001; 18.1 ± 8.3 vs. 10.9 ± 5.8, p < 0.001, respectively). Finally, left atrial EMD was higher in the vitiligo group, but we could not reach statistical significance (15.3 ± 6.9 vs. 13.2 ± 7.2, p = 0.33). Conclusion: We concluded that intra-atrial EMD and inter-atrial EMD were significantly prolonged in the vitiligo patients. Our results suggest that vitiligo patients are at risk for atrial fibrillation.

  • Open Access

    Results of Skin Prick Tests in Dermatology Outpatient Allergy Unit

    by Kemal Özyurt, Ragıp ERTAŞ, Emin Özlü, Muhammed Reşat AKKUŞ, Atıl AVCI, Mustafa Atasoy

    Objective: Skin prick test (SPT) is mainly used for diagnosis and follow-up of diseases like atopic dermatitis (AD), chronic urticaria (CU), allergic asthma (AA) and allegic rhinitis (AR). The aim of current study is to explore the results of SPT retrospectively which were performed in Dermatology Outpatient Allergy Unit (DOAU) for identifying indications and positivity. Methods: Results of SPT which were performed on 2014-2016 were investigated based on archives of DOAU. Results of SPT were analyzed from the SPT Forms which were prepared for each patient. Results: SPT were performed on 1916 individuals who admitted to DOAU during 2015-2016. AA was determined in 941, AR in 133 and dermatological diseases were 842 patients. SPT positive results, for at least one or more allergen agents, of patients with AA, AR and dermatological diseases were 92.1%, 71.4% and 50% respectively. Dermatological diseases included; except CU in 69 patients and AD in 55 patients. In the remaining 718 patients were diagnosed with dermatitis, idiopathic generalised pruritus (IGP) and other dermatological disorders. SPT positivity rates in CU was 55.1%, 52.7% in AD and 48.6% in several dermatological diseases. Conclusions: As a result, the rate of SPT positivity in patients with AA and AR were higher than both CU, AD and several dermatological diseases. The reason of this may be related with lesser role of type 1 hypersensivity reaction in etiopathogenesis of CU and AD, and/or improper SPT indications who were directed with diagnosis of several dermatological diseases.

  • Open Access

    Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria

    by Ragıp ERTAŞ, Kemal Özyurt, Çiğdem Karakükçü, Muhammet Reşat AKKUŞ, Emin Özlü, Atıl AVCI, Mustafa Atasoy

    Background/aim: Spontaneous wheals and/or angioedema lasting longer than six weeks are described as chronic spontaneous urticaria (CSU). Omalizumab is used for the treatment of antihistamine-resistant CSU. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), mean platelet volume (MPV), and platelet distribution width (PDW) are considered important indicators of inflammation and platelet activation in chronic diseases. We aimed to determine the NLR, PLR, MPV, and PDW levels in patients with CSU compared with healthy controls. We also aimed to investigate the effects of omalizumab therapy on these parameters in CSU patients. Materials and methods: This hospital-based, retrospective study included 143 patients with CSU and 132 healthy controls with a mean age of 40.0 +/- 13.17 and 42.0 +/- 16.34, respectively. Patients with equal or higher-than-baseline UAS scores at week 12 of omalizumab treatment were considered nonresponders, others were considered responders. We analyzed the neutrophils, lymphocytes, platelet counts, NLR, PLR, MPV, and PDW before, during, and after omalizumab treatment and compared the results with those of healthy controls. Results: CSU patients presented higher baseline MPV (P = 0.035) and lower baseline PDW values (P < 0.001) than healthy controls. There were statistically significant increases in the MPV (P < 0.001), MPV/platelet count (P = 0.005), and PDW (P = 0.003) and there was a statistically significant decrease in the NLR (P = 0.018) during omalizumab treatment. The percent increase of MPV was low in nonresponders (P = 0.009). Nonresponders had lower PDW values than responders (P = 0.040). Conclusion: The increase in the MPV and PDW may be due to platelet activation during omalizumab treatment. The decrease in the NLR may be regarded as an antiinflammatory effect of omalizumab. The effect of omalizumab on platelet and inflammatory markers may be used to discriminate the responders from nonresponders.